COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 112: Articles 1111-1120  | Next

Robust and Reliable de novo Protein Design: A Flow-Matching-Based Protein Generative Model Achieves Remarkably High Success Rates
Yan, J., Cui, Z., Yan, W., Chen, Y., Pu, M., Li, S., Ye, S.
10.1101/2025.04.29.651154 — Posted: 2025-04-29
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract
Hazell, N. C., Reyna, R. A., Bonam, S. R., Bei, J., Kumar, N., Nguyen, T. N., Plante, J. A., Walker, D. H., Wang, T., Plante, K. S., Hu, H.
10.1101/2025.04.28.650951 — Posted: 2025-04-29
Highly potent antiviral drug candidates targeting SARS-CoV-2 nsp3 and nsp5
Galais, M., HERLEM, G., HAIDAR AHMAD, S., Pasquereau, S., EL BABA, R., BELLEFROID, M., PLANT, E., MOROT-BIZOT, S., PICAUD, F., HERBEIN, G., Van Lint, C. M.
10.1101/2025.04.28.650947 — Posted: 2025-04-29
Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida
Levi, R., Mansuri, F., Jordan, M., Ladapo, J.
10.1101/2025.04.25.25326460 — Posted: 2025-04-29
Breakthrough infection elicits synergistic broadly neutralizing antibodies targeting non-dominant epitopes on RBD and NTD in an individual of inactivated SARS-CoV-2 vaccine
Wang, Z., Feng, H., Ling, L., Li, Y., Lu, M., Chen, X., Hu, L., Sun, Y., Du, R., Qin, R., Chen, X., Jiang, L., Zuo, T.
10.1101/2025.04.27.650832 — Posted: 2025-04-28
HEALTH SURVEILLANCE AND EPIDEMIOLOGICAL PROFILE OF SEVERE ACUTE RESPIRATORY SYNDROME DUE TO COVID-19 IN BRAZIL (2020-2024)
Candido-Sobrinho, S. A., Silva-Filho, J. Q. d., Junior, F. d. S., Feitosa Viana, V. A., Moreira Lima, A. A.
10.1101/2025.04.27.25326529 — Posted: 2025-04-28
Complement activation was not increased in patients with post-acute sequelae after mild SARS-CoV-2 infection: A prospective cohort study
Holmqvist, M., Sjöström, D. J., Carlson, K., Gullstrand, B., Bengtsson, A. A., Kahn, R., Mollnes, T. E., Akesson, P., Nilsson, P. H., Kahn, F.
10.1101/2025.04.26.25326246 — Posted: 2025-04-28
The effect of COVID-19 and socioeconomic inequalities on emergency department accesses for psychiatric conditions
SCHEPISI, C., Ventura, M., Di Napoli, A., Aragona, M., Ciampichini, R., Fano, V., Napoli, C., Pacifici, M., Rosini, C., Silvestri, C., Voller, F., Zucchi, A., Petrelli, A.
10.1101/2025.04.25.25326419 — Posted: 2025-04-28
Impact of the COVID-19 pandemic on the mycoplasma pneumoniae infections in children:a retrospective study at a tertiary hospital in Central China
Guo, P., Lei, Z., Zheng, X., Zhang, Y., Xia, Z.
10.1101/2025.04.25.25326390 — Posted: 2025-04-28
Genome-wide association studies of hospitalized influenza identify 4 risk loci and a relationship with COVID-19
XUE, X., CHAN, P.-C., SO, H.-C.
10.1101/2025.04.25.25325850 — Posted: 2025-04-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).